PMD PSYCHEMEDICS CORP revenue, earnings and financials
For the quarter ended December 31, 2024, PSYCHEMEDICS CORP reported revenue of $4.43M (down 11.5% from a year earlier), net income of $189K and diluted EPS of n/a; over the last four quarters revenue was $19.7M and net income −$1.86M; for the fiscal year ended December 2024 revenue was $19.7M, down 10.9% on the year before.
PMD annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $19.7M, gross profit $7.10M, operating income −$1.89M, net income −$1.86M (margin -9.5%), EPS n/a
- Fiscal year ended Dec 2023: revenue $22.1M, gross profit $8.41M, operating income −$2.92M, net income −$4.15M (margin -18.8%), EPS n/a
- Fiscal year ended Dec 2022: revenue $25.2M, gross profit $9.29M, operating income −$1.08M, net income −$1.08M (margin -4.3%), EPS −$0.19
- Fiscal year ended Dec 2021: revenue $24.9M, gross profit $10.3M, operating income $209K, net income −$665K (margin -2.7%), EPS −$0.12
PMD quarterly revenue and earnings
- Quarter ended Dec 31, 2024 (from the annual report): revenue $4.43M (down 11.5% year over year), net income $189K, EPS n/a
- Quarter ended Sep 30, 2024: revenue $5.18M (down 9.3% year over year), net income −$535K, EPS n/a
- Quarter ended Jun 30, 2024: revenue $4.73M (down 14.6% year over year), net income −$827K, EPS n/a
- Quarter ended Mar 31, 2024: revenue $5.36M (down 8.6% year over year), net income −$688K, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue $5.00M (down 12.4% year over year), net income −$945K, EPS n/a
- Quarter ended Sep 30, 2023: revenue $5.70M (down 12.5% year over year), net income −$2.10M, EPS −$0.36
- Quarter ended Jun 30, 2023: revenue $5.54M (down 15.0% year over year), net income −$726K, EPS −$0.13
- Quarter ended Mar 31, 2023: revenue $5.86M (down 10.0% year over year), net income −$384K, EPS −$0.07
- Quarter ended Dec 31, 2022 (from the annual report): revenue $5.70M (down 11.4% year over year), net income −$688K, EPS −$0.12
- Quarter ended Sep 30, 2022: revenue $6.52M (down 2.4% year over year), net income −$97.0K, EPS −$0.02
- Quarter ended Jun 30, 2022: revenue $6.51M (up 7.0% year over year), net income −$338K, EPS −$0.06
- Quarter ended Mar 31, 2022: revenue $6.51M (up 13.9% year over year), net income $39.0K, EPS $0.01
- Quarter ended Dec 31, 2021 (from the annual report): revenue $6.44M, net income −$1.62M, EPS −$0.28
- Quarter ended Sep 30, 2021: revenue $6.67M, net income $739K, EPS $0.13
- Quarter ended Jun 30, 2021: revenue $6.09M, net income $134K, EPS $0.02
- Quarter ended Mar 31, 2021: revenue $5.71M, net income $83.0K, EPS $0.01
PMD cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow $929K, share buybacks $2.56M
- Fiscal year ended Dec 2023: operating cash flow −$1.48M, share buybacks $0, dividends $0.14 per share
- Fiscal year ended Dec 2022: operating cash flow $4.89M, share buybacks n/a, dividends $0.14 per share
- Fiscal year ended Dec 2021: operating cash flow $414K, share buybacks n/a, dividends $0.05 per share
PMD balance sheet
- Dec 31, 2024: cash $1.42M, total assets $8.32M, total liabilities $3.19M, shareholders' equity $5.13M
- Sep 30, 2024: cash $1.41M, total assets $9.84M, total liabilities $4.39M, shareholders' equity $5.45M
- Jun 30, 2024: cash $1.43M, total assets $10.1M, total liabilities $4.37M, shareholders' equity $5.74M
- Mar 31, 2024: cash $1.42M, total assets $11.2M, total liabilities $4.87M, shareholders' equity $6.28M
- Dec 31, 2023: cash $1.96M, total assets $12.3M, total liabilities $5.65M, shareholders' equity $6.67M, long-term debt $0
- Sep 30, 2023: cash $1.37M, total assets $14.1M, total liabilities $6.68M, shareholders' equity $7.43M, long-term debt $77.0K
- Jun 30, 2023: cash $2.45M, total assets $16.4M, total liabilities $7.26M, shareholders' equity $9.13M, long-term debt $154K
- Mar 31, 2023: cash $4.38M, total assets $17.9M, total liabilities $7.74M, shareholders' equity $10.2M, long-term debt $230K
What is PMD's revenue?
PSYCHEMEDICS CORP reported $19.7M of revenue over its last four quarters, through December 31, 2024.
Is PMD profitable?
No. PSYCHEMEDICS CORP lost $1.86M over the last four quarters.
Does PMD pay a dividend?
PSYCHEMEDICS CORP paid $0.14 per share in dividends in the fiscal year ended December 2023.